Tresiba

(Insulin degludec)

Tresiba

Drug updated on 11/10/2023

Dosage FormInjection (subcutaneous; 300 units/3 mL, 600 units/3 mL, 1000 units/10 mL)
Drug ClassLong-acting human insulin analogs
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • To improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Product Monograph / Prescribing Information

Document TitleYearSource
Tresiba (insulin degludec) Prescribing Information.2022Novo Nordisk Inc., Plainsboro, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline2023Journal of diabetes
Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta-analysis 2023Journal of diabetes
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics2023Diabetes, obesity & metabolism
Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison. 2022International Journal of Clinical Pharmacy
Insulin degludec versus insulin glargine on glycemic variability in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. 2022Frontiers in Endocrinology
Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.2022Clinical Therapeutics
Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials2022Diabetes & metabolic syndrome
Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis2022Cureus
Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.2021Naunyn-Schmiedeberg’s Archives of Pharmacology
Safety and efficacy of long-acting insulins degludec and glargine among Asian patients with type 2 diabetes mellitus: a meta-analysis.2021Cureus
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus2021The Cochrane database of systematic reviews
Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials2020The Cochrane database of systematic reviews
(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus2020The Cochrane database of systematic reviews
Insulin degludec, a novel ultra-long-acting basal insulin versus insulin glargine for the management of type 2 diabetes: a systematic review and meta-analysis.2019Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders
Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis2019Diabetes, obesity & metabolism
Efficacy and safety of insulin degludec versus insulin glargine: a systematic review and meta-analysis of fifteen clinical trials.2018International Journal of Endocrinology
Australian public assessment report for insulin degludec.2018Australian Government Department of Health
Comparative benefits and harms of basal insulin analogues for type 2 diabetes: A systematic review and network meta-analysis.2018Annals of Internal Medicine
Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials2018International journal of endocrinology
Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis 2018Value in health
Understanding concentrated insulins: a systematic review of randomized controlled trials2018Current medical research and opinion